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The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the
most extraordinary of any naturally-occurring psychedelic substance. Users consistently
report the complete replacement of normal subjective experience with a novel “alternate
universe,” often densely populated with a variety of strange objects and other
highly complex visual content, including what appear to be sentient “beings.” The
phenomenology of the DMT state is of great interest to psychology and calls for
rigorous academic enquiry. The extremely short duration of DMT effects—less than
20min—militates against single dose administration as the ideal model for such enquiry.
Using pharmacokinetic modeling and DMT blood sampling data, we demonstrate that
the unique pharmacological characteristics of DMT, which also include a rapid onset
and lack of acute tolerance to its subjective effects, make it amenable to administration
by target-controlled intravenous infusion. This is a technology developed to maintain
a stable brain concentration of anesthetic drugs during surgery. Simulations of our
model demonstrate that this approach will allow research subjects to be induced into
a stable and prolonged DMT experience, making it possible to carefully observe its
psychological contents, and provide more extensive accounts for subsequent analyses.
This model would also be valuable in performing functional neuroimaging, where subjects
are required to remain under the influence of the drug for extended periods. Finally,
target-controlled intravenous infusion of DMT may aid the development of unique
psychotherapeutic applications of this psychedelic agent.
Keywords: psychedelic drugs, dimethyltryptamine, ayahuasca, hallucinations, consciousness, intravenous
infusion, pharmacokinetic modeling
INTRODUCTION
N,N-dimethyltryptamine (DMT) produces some of the most extraordinary changes in
consciousness of any naturally-occurring psychedelic substance. Users consistently report the
complete replacement of awareness of the normal waking world with a bizarre and complex
“alternate universe” filled with a variety of visual objects, including what appear to be sentient,
intelligent, and powerful “beings,” many of which actively interact with the individual (Strassman,
2001, 2008; Luke, 2011; Gallimore, 2013). Furthermore, the endogenous production of DMT
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in humans is well-established (Barker et al., 2012), although the
biological significance of this remains to be elucidated. DMT is
actively transported across the blood brain barrier in rats and
dogs (Sangiah et al., 1979; Takahashi et al., 1985; Yanai et al.,
1986), and a similar mechanism plausibly exists in humans. DMT
is also a substrate for the human serotonin and monoamine
vesicular transporters (Cozzi et al., 2009). The key enzyme for
its production, indolethylamine N-methyltransferase, has been
detected in the brain, pineal gland, and retina of primates (Cozzi
et al., 2011). Taken together, these data suggest that DMT may
have a significant role in human neurophysiology, consciousness,
and the visual system.
Clinical psychedelic drug research has resumed after a
generation’s hiatus, and its scope is expanding rapidly. Modern
functional neuroimaging techniques are revealing the neural
accompaniment of these altered states of consciousness
(Vollenweider et al., 1997; Carhart-Harris et al., 2012; Roseman
et al., 2014; Tagliazucchi et al., 2014; Gallimore, 2015; Nichols,
2016). However, comparable thoroughgoing analyses of their
phenomenology are lacking. This is surprising because of how
unusual and highly replicable are the subjective effects of the
psychedelic drugs in general, in particular those of DMT. The
profound and easily reproducible effects of DMT and other
psychedelics may provide valuable insights into the structure of
the human mind—the central focus of psychology itself. As such,
in addition to their neural correlates, the phenomenology and
content of the DMT state calls for rigorous academic enquiry.
Studies of DMT in humans began in the 1950s (Boszormenyi
and Szara, 1958; Sai-Halasz et al., 1958; Szara, 2007; Gallimore
and Luke, 2015), when its mind-altering effects were explored as
a form of chemically-induced psychosis. However, such studies
simply classified the complex visual effects as “hallucinations”
with no further analysis. Neither do most modern studies
purporting to examine the psychological effects of psychedelic
drugs routinely provide detailed descriptions of the altered state
(Riba et al., 2001; Gouzoulis-Mayfrank et al., 2005). An exception
is the largest clinical study of DMT to date, which paid careful
attention to the content of the DMT experiences of nearly five
dozen volunteers administered a wide range of DMT doses
(Strassman et al., 1994; Strassman, 1995, 2001).
The time course of DMT administered via inhalation of
vaporized freebase or intravenous injection of a water-soluble
salt is brief. The onset is rapid and overwhelming, with
full effects noted within 2min of administration. Subjective
effects are usually fully resolved within 20–30min. A powerful
“rush” heralds the effect of a fully psychedelic dose of DMT,
marked by a sense of tremendous acceleration and psychic
and somatic tension. These culminate in the dissociation of
consciousness from bodily awareness and entry into a “world
of light” characterized by extremely complex visions. Users
frequently report the sense of receiving “information,” as well
as the conviction that what is being observed feels as if it
were an autonomous alternate world rather than a dream or
hallucination. A commonly heard refrain is that the experience
was “more real than real.”
The inability to induce psychological tolerance to repeated
full-psychedelic doses of intravenous DMT administered
by bolus injection (Strassman et al., 1996) makes it
unique among classic serotonergic psychedelics: e.g., LSD
(Belleville et al., 1956). This property renders DMT amenable
to administration by continuous intravenous infusion,
in which the drug is administered at a predetermined
rate over a period of time and subjective effects can be
prolonged.
Gouzoulis-Mayfrank et al. (2005) used such an approach
to study the psychological effects of both DMT and ketamine.
This group’s infusion rates were established by observing the
subjective effects of the drug, rather than taking into account its
underlying pharmacokinetics or pharmacodynamics. That three
of the 15 subjects dropped out of the study because of adverse
psychological reactions suggests that this model resulted in an
overly high infusion rate. A more pharmacokinetically-informed
approach to infusion will allow the attainment and maintenance
of a stable blood—and presumably brain—concentration of
DMT, and thus provide a safe and effective prolonged immersion
in the unique DMT state.
METHODS AND RESULTS
Target-controlled intravenous infusion is a methodology
developed for use in general anesthesia, during which it is
essential that the concentration of drug at the target site (the
brain) be established and stably maintained (Kenny and White,
1990; Absalom et al., 2016). If drug levels drop too low, the
patient may rouse during the procedure, and rising brain levels
may result in potentially life-threatening effects. Computer-
assisted infusion devices are now routinely used to ensure
anesthetic levels remain within the required therapeutic window.
The foundation of these systems is a mathematical model of
the pharmacokinetics and pharmacodynamics of the anesthetic
drug (Gambus and Troconiz, 2015). For a drug to be suitable
for target-controlled infusion it should ideally possess a number
of characteristics listed in Table 1 (Miller, 1994). Fortunately,
the water-soluble DMT salt used for intravenous administration
meets all of these criteria.
As a drug is introduced into the body by intravenous
injection, it is rapidly diluted and distributed by the blood.
It also equilibrates to various degrees with peripheral
tissues—dependent on specific drug properties and degree
of vascularization of the relevant tissues—and with the effect
site itself. The elimination of the drug from the body also begins
immediately, by a combination of enzymatic transformation,
and urinary and/or biliary excretion. Pharmacokinetic models
must take into account both intrinsic and drug-specific factors
that affect drug absorption, distribution, and elimination. Single-
compartment models only consider the rapid dilution of the
drug in the main vascular compartment, whereas two- and three-
compartment models also take into account equilibration of
the drug with peripheral tissues. The pharmacokinetics of most
anesthetics are best fitted to either a two- or three-compartment
model (Shafer and Gregg, 1992). Since DMT turns out to be best
fitted to a two-compartment model (see later), only this type will
be described here (Figure 1).
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TABLE 1 | Desired characteristics of drugs for continuous IV infusion
(Miller, 1994).
1. Water-soluble
2. Rapid onset of action
3. Short duration of effect
4. Lack of tolerance
5. High clearance rate with minimal tendency for accumulation
6. No active metabolites
7. High therapeutic index
8. Minimal side-effects
Drug is introduced into the central compartment to rapidly
achieve a plasma concentration, CT , dependent on the volume
of distribution, VC. The drug is removed from the central
compartment, quantified by a drop in plasma concentration
over time, by both elimination and equilibration with the
peripheral compartment. This rate of plasma concentration
decline is controlled by the elimination rate constant, k10, and
the relative rates of movement from the central to the peripheral
compartment, k12, and in the opposite direction, k21. The overall
rate, RT , obeys the differential equation:
RT = CT × VC
(
k10 + k12e
−k21 t
)
Complete equilibration with the peripheral compartment is
reflected in the exponential term decaying to zero and the steady
state elimination rate, RSS, is:
RSS = CT × VCk10
Transfer from the central compartment to the effect site, R1E, is
generally modeled as a first-order process with rate constant, k1e:
R1E = CTk1e
To maintain a constant plasma, and thus effect site,
concentration, the infusion rate must equal the overall removal
rate, RT . Since this is not constant, except at steady state, the
infusion rate must be adjusted to approximate the decline
in RT over time. This requires the determination of the
pharmacokinetic parameters: VC, k10, k12, and k21, which can
be achieved by fitting time-series blood sampling data to a
pharmacokinetic model.
To establish that the pharmacokinetics of DMT make it
suitable for target-controlled infusion, we used DMT plasma
concentration data from a previous study (Strassman and Qualls,
1994). The details are provided in the original paper. Briefly,
each subject receiving a “fully psychedelic” dose of DMT was
administered either 0.2 or 0.4mg/kg DMT fumarate over 30 s
through an indwelling forearm intravenous catheter, followed
by a 15 s flush with sterile saline. Blood samples were drawn
before the infusion and at 2, 5, 10, 15, 30, and 60min from the
end of the infusion (45 s after the infusion began). Plasma DMT
concentration in each sample was then determined using gas
chromatography-mass spectrometry (GC-MS). A total of nine
subjects were used in the analysis (9 sets each of 0.4 and 0.2mg/kg
time series data).
These time-series data were fitted to one-, two-, and three-
compartment pharmacokinetic models. The naïve averaged data
approach is the most straightforward technique for fitting
pharmacokinetic data, in which plasma concentration at each
time point is averaged over all subjects to generate a mean dose-
response curve. This curve is then fitted to a pharmacokinetic
model. However, methods taking into account both fixed and
random effects on the dose-response—for example, non-linear
mixed effects modeling (NON-MEM)—often give more reliable
parameter estimates. These methods also allow identification of
parameter covariates, such as weight or age (Mould and Upton,
2012).
Using the Matlab Simbiology toolkit (Mathworks, Inc.),
we fitted the 0.2 and 0.4mg/kg time- series data separately.
Both datasets were best fitted to a two-compartment model
with enzymatic clearance, consistent with Michaelis-Menten
kinetics (Figure 2). This comports with the well-established rapid
metabolism of DMT by monoamine oxidase (MAO) A (Barker
et al., 1980; Sitaram et al., 1987; Riba et al., 2015). Table 2 shows
the population parameter estimates obtained.
These parameter estimates are for an “average” individual
(i.e., obtained from the mean plasma concentration across
the nine subjects at each time point), although the dose-
concentration response varied considerably among subjects. The
mean coefficients of variation in plasma DMT concentration,
between 2 and 30min post-infusion, across the 0.2 and 0.4mg/kg
groups were 83 and 58%, respectively. There was also variation in
the estimated parameters depending on the dose. Since 0.4mg/kg
was the most reliable dose for inducing the fully psychedelic
DMT experience, we sought an infusion model that reaches
and maintains the effect site concentrations observed with this
dose. Therefore, the 0.4mg/kg parameter set was chosen for
development of the infusion model. However, comparable results
were obtained using the alternative parameter set.
Having established the model parameters, we then sought to
extend the model to include the effect site (brain) concentration.
The model was simulated using an infusion protocol employed
in the original study (i.e., 0.4mg/kg infusion over 30 s). While
subjects were unable to communicate during the peak DMT
effects, a number of observations indicated that these peak
effects in each subject occurred at approximately 3min from
the beginning of the infusion. First, the lower doses of drug
(0.05 and 0.1mg/kg) were not incapacitating, and provided the
opportunity for volunteers to describe the onset, peak, and
dissipation of drug effects in a running commentary narrative
as they were occurring. With these lower doses, effects peaked
at approximately 3min, began dissipating quickly, and were
resolved by 15–20min. That the time course of peak DMT blood
levels is identical across the spectrum of doses suggests that the
correspondence between the time course of peak DMT effects
and peak plasma levels at higher incapacitating doses also holds
true. Acute autonomic responses to DMT also reached their
highest levels between 2 and 5min from the end of the infusion,
usually at the former time point. These included pupil diameter,
heart rate, and mean arterial blood pressure.
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FIGURE 1 | Structure of a standard two-compartment (plus effect site) pharmacokinetic model with transfer and elimination rates.
At the peak effect time, the drug concentration in the central
compartment is equal to the concentration at the effect site. This
makes it straightforward to model the effect site concentration
using the first-order rate equations:
R1E = CTk1e
RE0 = CTke0
where R1E is the rate of transfer of the drug from the central
compartment to the effect site and RE0 is the elimination rate
from the effect site, controlled by the rate constants k1e and
ke0, respectively. The parameters were tuned such that the peak
effect site concentration was reached at ∼3min. The resulting
simulation is plotted in Figure 3 and seems to fit the observations
well.
Typically, the subject would appear to transition into full
dissociation from the external world toward the end of the 15 s
saline flush following the 30 s DMT infusion. This suggests that
“breakthrough” into the DMT space occurs when the effect site
concentration reaches ∼60 ng/ml. The subject then remains in
the “space” for the next 6–7min, with the peak effect occurring
at 3min, when the effect site concentration is just over 100
ng/ml.
TABLE 2 | Fitted pharmacokinetic parameters for 2-compartment model
with enzymatic clearance.
Vc (L) Vp (L) Km (mg/L) Vm (mg/min) Q12 (L/min)
0.4mg/kg 0.093 0.34 21.48 2.00 0.056
0.2mg/kg 0.14 0.23 9.52 1.07 0.046
k12 = Q12/ Vc; k21 = Q12/Vp
Clinical observation of the subjects appears to match this
time course, with their maximum level of absorption in the
subjective experience occurring at 4–5min, likely as the initial
rush and disorientation began to subside. For example, subjects
demonstrated seemingly involuntary deep rhythmic breathing,
the mouth being open in a passive regressed manner, and REM-
like eye movements behind closed lids. Conversely, subjects
appeared to be less under the influence of a high dose of DMT
as early as 5min; e.g., moving their fingers, licking their lips or
yawning, taking a deep sighing breath, and stretching their feet,
suggesting that the acute drug effect was beginning to lighten.
Tellingly, almost every volunteer did not remember the 2min
blood pressuremeasurement, whereas almost all remembered the
5min measurement, which is when our model suggests the effect
site concentration was again approaching ∼60 ng/ml, when exit
from the full DMT intoxication occurs.
Having simulated the infusion protocol used in the original
study, we then used the model to develop an infusion protocol
that would bring the effect site concentration smoothly to the
predetermined level to ensure “breakthrough” without significant
overshoot, and to keep the concentration stable indefinitely. A
100 ng/ml brain concentration was typically achieved during the
most intense period of the DMT experience with a 0.4mg/kg
bolus, and this concentration was chosen as the desired target
concentration for the infusion. However, lower or higher
concentrations can be achieved using an analogous protocol with
modified infusion rates.
We developed our infusion model using the bolus-
elimination-transfer (B.E.T.) methodology, upon which
anesthesia infusion protocols are often based (Coetzee, 2012). An
initial bolus, B0, is used to rapidly bring the plasma concentration
to the desired level, CT :
B0 = CTVC
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FIGURE 2 | Fitting of two-compartment model with enzymatic clearance to blood sample data. (A) 0.4mg/kg bolus; (B) 0.2mg/kg bolus.
The infusion rate is then calculated to equal the sum of the
elimination rate, E, and the transfer rate from the central to the
peripheral compartment, T.
E = VC × k10CT
T = VC × k12e
−k21tCT
The sum of E and T gives the overall infusion rate as defined
earlier:
RT = CT × VC
(
k10 + k12e
−k21t
)
Since the model-fitting established that E is dominated by
enzymatic clearance, k10 must be reformulated in terms of
Michaelis-Menten kinetics:
k10CT =
VmCT
Km + CT
This gives the maintenance infusion rate, RT , as:
RT =
VmCT
Km + CT
+ CTVCk12e
−k21t
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FIGURE 3 | Simulated time course of DMT brain concentration following a 0.4mg/kg bolus.
Since the first term in the RT equation depends only on the
plasma concentration, it becomes constant when a steady state
concentration is reached. The exponential term is only important
before steady state is reached, in the initial stage of the infusion.
It then decays to zero. Assuming the steady state concentration
is the desired effect site concentration, CT , the maintenance
infusion rate, Rss, can be calculated:
Rss =
VmCT
Km + CT
Using the estimated model parameters, this gives a steady state
infusion rate of 0.93 mg/min. However, during the first few
min of the infusion, the exponential term is large; i.e., there
is rapid transfer of drug from the central to the peripheral
compartment. This rate of transfer peaks at 3.3 mg/min, at
around 2.3min, before declining rapidly. The infusion rate must
be set to compensate for this transfer, being decreased gradually
until Rss is reached. This variable infusion rate is essential to
attaining and maintaining a stable effect site concentration. If
the initial rate is too low following the initial bolus, the effect
site concentration plummets well below that desired and is
not maintained. Conversely, if a high initial infusion rate is
maintained, the effect site concentration continues to increase.
It is possible that this accounts for the relatively high rate
of volunteers dropping out of the Gouzoulis-Mayfrank study
(Gouzoulis-Mayfrank et al., 2005).
To examine the possibility of effect site concentration
overshoot, we performed simulations using the Gouzoulis-
Mayfrank infusion protocol: 0.3mg/kg bolus, followed by an
infusion beginning at 1.5min, at a rate of 0.02mg/kg/min over
84min. Figure 4 shows the expected effect site concentration
over this infusion period for a 75 kg subject. The initial
bolus produces an effect site concentration of 80 ng/ml; i.e.,
a breakthrough dose. Once the infusion begins, however, the
concentration rises steadily, and reaches 150 ng/ml by the end of
the session. This is a very high concentration and is certain to
produce extremely intense effects in almost all individuals.
Using our PK model, we developed an infusion protocol that
maintains an effect site concentration of ∼100 ng/ml in a 75 kg
subject (Figure 5). An initial bolus of 25mg infused over 30 s
rapidly brings the effect site concentration to just over 100 ng/ml.
Although the plasma concentration spikes at over 200 ng/ml,
the desired effect site concentration is reached smoothly with
very little overshoot. The infusion begins at 2min at a rate of
4.2 mg/min. The infusion is updated every min, and decreases
according to the peripheral transfer rate decay (the exponential
term in the RT equation). Steady state does not occur until after
20min of infusion, after which a constant maintenance infusion
rate of 0.93 mg/min is employed.
The blood sample data used in this work was from a
previous study (Strassman and Qualls, 1994) approved by the
Scientific Advisory Committee of the General Clinical Research
Center (GCRC) and Human Research Review Committee of the
University of New Mexico School of Medicine, Albuquerque, the
New Mexico State Pharmacy Board, the US Drug Enforcement
Administration, and the US Food and Drug Administration.
Witnessed written informed consent was obtained from all
subjects, and confidentiality and anonymity were maintained
throughout the study.
DISCUSSION
The phenomenological content of dream states (Schredl and
Hofmann, 2003; Kahan and Laberge, 2011; Thomas et al., 2015)
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FIGURE 4 | Simulated time course of plasma and effect site DMT concentration using the (Gouzoulis-Mayfrank et al., 2005) protocol.
and hallucinations in psychotic disorders have been studied
extensively (Jardri et al., 2014; Wilkinson, 2014), with the aim
of deepening our understanding of the structure of normal
and abnormal states of consciousness. However, whilst the
endogenous human hallucinogen DMT reliably and reproducibly
generates one of the most unusual states of consciousness
available, its phenomenology has only begun to be characterized.
One of the reasons for this is its short duration of action.
A technology for extending DMT experiences in a controlled
manner beyond what is achievable using bolus administration
therefore would be of great value.
Modern target-controlled infusion protocols employ
algorithms that allow the infusion rate to be calculated and
adjusted in real time, such that the effect site drug concentration
can be raised and lowered in order to control, for example, the
level of anesthesia (Bailey and Shafer, 1991; Shafer and Gregg,
1992). Our analysis highlights the potential of using the target-
controlled infusion methodology for extended DMT sessions.
Using time-series blood sampling data and pharmacokinetic
modeling, we propose that the unique pharmacological
characteristics of DMT make it suitable for administration by
target-controlled intravenous infusion. These characteristics
include a rapid and short-acting effect, and lack of acute
tolerance to its subjective effects. Such methods could be used
to control the depth of the experience during a DMT session,
moving the subject into more intense levels of DMT intoxication
or lowering them back into more manageable levels to provide
both respite and easier communication with the research
team.
The methodology developed here is the first step toward a
protocol that is ready for use in research subjects. The purpose
of this modeling is to provide a proof-of-principle that the
pharmacokinetic and pharmacodynamic properties of DMT are
such that stable effect site concentrations can be achieved using
target-controlled infusion. More extensive sampling and more
detailed pharmacokinetic modeling are required to establish
definitive population parameters, the extent of inter- and intra-
subject variability, and covariates.
As with any drug administered by target-controlled infusion,
subject covariates including weight, age, gender, and liver
function create significant inter-subject and intra-subject
variability in the dose-concentration response (White et al.,
2008). In this study, the mean coefficients of variation in plasma
DMT concentration across the 0.2 and 0.4mg/kg groups were
83 and 58%, respectively. Although this variability appears large,
dose-response coefficients of variation between 40 and 60% for
anesthetic agents (e.g., propofol) administered by bolus injection
are typical. However, the response variability for continuous
infusion protocols is always lower than that observed for bolus
injection (Hu et al., 2005). Even with well-established infusion
protocols, plasma drug concentrations typically deviate 20–30%
above or below the target concentration (Coetzee et al., 1995).
For this reason, most anesthesia infusion protocols undergo a
number of iterations as pharmacokinetic models are updated
and refined.
Thus, the variability observed in this initial modeling
study does not preclude the development of a target-
controlled infusion protocol for DMT. In addition, despite
the large dose-concentration variability, the variability in the
relationship between the dose and the subjective response was
much lower. The coefficients of variation of the subjective
response scores, as measured by the Hallucinogen Rating
Scale, an instrument designed specifically to assess the DMT
effect, were 46 and 32% for the 0.2 and 0.4mg/kg groups,
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FIGURE 5 | Simulated time course of infusion protocol designed to reach and maintain effect site concentration of ∼100ng/ml.
respectively (Strassman et al., 1994). This 45% lower subjective
response variability compared to dose-concentration variability
suggests that a broader target concentration window exists
for attainment of the desired subjective effect than might be
predicted from dose-concentration variability alone. Therefore,
the target concentration accuracy typically achieved with
anesthetic agents is likely to be suitable in a DMT infusion
protocol.
The DMT-containing plant-based decoction ayahuasca
provides an extended “DMT experience” lasting several
hour (Shanon, 2003; Frenopoulo, 2005; Schmidt, 2012). The
phenomenology of the ayahuasca state has been the subject of
more extensive analyses than that of pure DMT (Shanon, 2005).
However, to render the preparation orally-active, the ayahuasca
brew must contain both a DMT-containing plant as well as one
containing a beta-carboline MAO inhibitor, such as harmaline
(McKenna et al., 1984). Since beta-carbolines themselves possess
psychoactive properties and may potentiate the effects of other
psychoactive alkaloids in the plant mixture (Callaway et al.,
1999), the subjective effects of ayahuasca differ from those of
pure DMT. Furthermore, it is not possible to precisely regulate
and maintain the effect-site DMT concentration with an oral
preparation.
There are a number of research questions that a successful
application of target-controlled IV infusion of DMTmay address.
For example, the maximum DMT effect may extend further than
what has been previously described in bolus studies. Very high
acute doses of DMT typically produce a delirium, and users are
unable to recall details of the experience. However, this may
result from too rapidly attaining supra-maximal concentrations
of drug. Using the method described here, it may be possible to
move the individual gradually into a greater level of intoxication
while maintaining the characteristic mental clarity associated
with fully psychedelic doses.
In addition, this model is applicable to studies of the neural
correlates of the psychedelic state as revealed by modern
functional neuroimaging techniques, which are also of great
interest (Carhart-Harris et al., 2016; Speth et al., 2016). Since
such protocols usually require the research subject to be under
the influence of the drug for an extended period of time, our
methodology would benefit these investigations as well.
Finally, there are potential psychotherapeutic applications.
With the resumption of clinical research with psychedelic drugs,
projects confirming and extending early research demonstrating
the benefit of psychedelic drug-assisted psychotherapy are
playing a prominent role. The conditions to which these novel
treatments are being applied include depression (Berman et al.,
2000; Aan Het Rot et al., 2010; Buchborn et al., 2014), obsessive-
compulsive disorder (Moreno and Delgado, 1997), dysphoric
psychological accompaniments of terminal illness (Grof et al.,
1973; Grob et al., 2011), prisoner recidivism (Hendricks
et al., 2014), and substance abuse disorders—including alcohol
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(Bogenschutz et al., 2015) and tobacco (Mangini, 1998; Krebs
and Johansen, 2012). All of the psychedelic substances being
used in these studies—LSD, psilocybin, and ayahuasca—exert
their effects over the course of 6–12 h, consistent with their
pharmacokinetic profiles.
One of the advantages of the rapid onset and short duration
of intravenous DMT effects is the ability to enter into and exit
out of a highly altered state in short order. The therapeutic
potential of this characteristic of DMT was illustrated by an
unexpected finding in the DMT tolerance study (Strassman
et al., 1996). Normal control volunteers received four fully
psychedelic 0.3mg/kg doses of DMT at 30min intervals. During
the 10–15min of relative lucidity between doses, they were quite
capable of describing both the effects they had just undergone
as well as what they anticipated would be the effects of the
subsequent dose(s). The overwhelming effects of a psychedelic
dose of DMT contributed to a heady and dynamic psychological
confluence of self-disclosure, anticipation, anxiety, vulnerability,
and intimacy. In addition, we found that nearly every subject’s
sessions contained an ongoing set of themes, or “storyline.” These
themes began with the first dose, evolved over the following two,
and resolved and/or culminated in the fourth. The opportunity
provided by talking with a therapeutically-trained research team
during the inter-bolus periods contributed to the psychological
work that these normal volunteers were able to do. We doubt
that this would have been possible if the volunteers were under
the influence of the drug unabatedly for that same 2.5 h period.
This paradigm of a continuous target-controlled infusion
similarly could be turned to therapeutic purposes in a patient
population. Using this model, patients could be “titrated” for both
the duration and intensity of the DMT state that was most useful
for augmenting the psychotherapeutic process. For example, in
the case of working through trauma, re-experiencing the feared
stimulus in the altered state might be initiated with induction
into a mildly altered state of relatively brief duration. In the
course of treatment, a more prolonged and intense altered level
of consciousness could be applied to a more extensive working
through process, broadening and deepening the therapeutic gains
begun with shorter and lighter exposures.
In summary, we have described the rationale, and presented
the requisite pharmacokinetic calculations, for the development
of target-controlled intravenous infusion of the powerful
endogenous psychedelic substance, DMT. The successful
demonstration of this model would provide a valuable tool in
determining the role of DMT in normal and altered states of
consciousness, and have broad psycho-heuristic, functional
imaging, and clinical applicability.
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